CALC today
$1.22-$0.02 (-1.61%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bearish
Daily trend turns up above $2.06
Key levels
Resistance$1.84
Resistance$1.61
Support$1.16
Latest news & SEC filings
EarningsCalciMedica posts third quarter 2026 financial results, gives clinical and corporate updates
EarningsCalciMedica posts smaller quarterly loss than analysts expected
SEC FilingCalciMedica, Inc. filed a report on a major company event (Form 8-K)
All CALC news →About CalciMedica
CalciMedica develops drugs for severe conditions driven by inflammation, immune responses, and cellular injury. Its treatments target CRAC channels, and its main candidate, Auxora, is an intravenous small-molecule inhibitor tested in acute pancreatitis, kidney injury with breathing failure, and pancreatic damage in children. Another candidate, CM5480, is in preclinical work for pulmonary arterial hypertension. The company runs studies in the United States and other countries.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
CalciMedica, Inc. (CALC)
What Is the Price Target for CALC?
SEPT Low Target
$9.00
SEPT Mid Target
$9.00
SEPT High Target
$9.00
Analyst Consensus
$9.00
Is CALC a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CALC.
Start Free Trial →Is CALC Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$6.96
0
Moat Score
NONE
1/9
Piotroski Score
-23.6
Altman Z-Score
What Is Smart Money Doing with CALC?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CALC Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-61.48%
FCF Growth YoY
-0.3%
Revenue Trend
UNKNOWN
Dark Pool Trades for CALC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CALC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:46:05 | $1.24 | 1,400 | $$2K | BUY |
| 20:29:04 | $1.21 | 1,612 | $$2K | SELL |
| 19:31:38 | $1.24 | 1,054 | $$1K | SELL |
| 18:06:46 | $1.25 | 5,000 | $$6K | BUY |
| 15:45:00 | $1.40 | 3,511 | $$5K | BUY |
5 dark pool trades shown · $$16K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for CalciMedica, Inc. (CALC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CALC — frequently asked questions
What is CALC stock price today?
CalciMedica, Inc. (CALC) is at $1.22, down 1.61% (-$0.02) at the Nov 12, 2026 close.
Why is CALC stock moving today?
Latest CALC news — Nov 11, 2026: CalciMedica posts third quarter 2026 financial results, gives clinical and corporate updates · Nov 10, 2026: CalciMedica posts smaller quarterly loss than analysts expected
What is the CALC price target?
The average analyst price target for CALC is $9.00, ranging from $9 to $9, based on 1 analysts. Latest: Guggenheim initiates on Aug 20, 2026.
What do analysts rate CALC?
Analyst ratings for CALC: 1 Buy, 0 Hold, 0 Sell — consensus Buy.
Did CALC beat earnings?
CALC last reported on Aug 11, 2026: EPS -$2.25 vs -$1.43 expected — a miss of 57.9%.
What are CALC support and resistance levels?
Support: $1.16. Resistance: $1.61, $1.84, $2.06.
What are insiders doing with CALC?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on CALC?
Nov 11, 2026: CalciMedica posts third quarter 2026 financial results, gives clinical and corporate updates · Nov 10, 2026: CalciMedica posts smaller quarterly loss than analysts expected · Nov 10, 2026: CalciMedica, Inc. filed a report on a major company event (Form 8-K)